Skip Navigation

Journal of Antimicrobial Chemotherapy 2008 62(Supplement 2):ii1; doi:10.1093/jac/dkn419
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jenks, P.
Right arrow Articles by Kerr, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jenks, P.
Right arrow Articles by Kerr, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

This article appears in the following Journal of Antimicrobial Chemotherapy issue: The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project 1999/2000-2006/7 [View the issue table of contents]

Preface

Preface

Peter Jenks, Alan Johnson and Kevin Kerr

The emergence and spread of strains of bacteria resistant to antimicrobial agents is one of the major public health challenges of our time. There is abundant evidence that treatment of bacterial infections with antibiotics to which the infecting pathogen is resistant is associated with increased morbidity, mortality and cost. As much prescribing of antibiotics is empirical, knowledge of the prevalence and epidemiology of resistance is therefore an essential component of the management of patients with infections.

The cornerstone of epidemiology is surveillance. In recognition of this, the British Society for Antimicrobial Chemotherapy (BSAC) established two programmes of surveillance of resistance among the bacterial pathogens causing respiratory tract infections and bacteraemia, respectively. Both surveillance programmes were funded by a consortium of pharmaceutical companies, but are managed by the Society. Surveillance has been defined as the generation of information for action, and to this end the BSAC have made the surveillance data readily available in a timely manner through the BSAC website. This Supplement, however, has allowed the collation and presentation of data on the trends in resistance to be presented in their entirety, together with papers providing the background to the programme, a description of the surveillance protocols and the methods used for analysis, and the value and implications of the findings. We feel this is a valuable contribution to our understanding of the problem of antimicrobial resistance and welcome the opportunity to share this information with the Journal readership.

Transparency declarations

All three Editors have received honoraria or funding from various pharmaceutical companies for speaking, conference attendance, research work and consultancy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jenks, P.
Right arrow Articles by Kerr, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jenks, P.
Right arrow Articles by Kerr, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?